Literature DB >> 21410640

Prognostic relevance of an asymptomatic venous thromboembolism in patients with cancer.

F Dentali, W Ageno, M Giorgi Pierfranceschi, M G Pierfranceschi, D Imberti, A Malato, C Nitti, A Salvi, S Siragusa, A Squizzato, J Vitale, G Agnelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21410640     DOI： 10.1111/j.1538-7836.2011.04259.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  16 in total

1.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Risk factors for incident venous thromboembolism in active cancer patients: A population based case-control study.

Authors:  Aneel A Ashrani; Rachel E Gullerud; Tanya M Petterson; Randolph S Marks; Kent R Bailey; John A Heit
Journal:  Thromb Res       Date:  2016-01-05       Impact factor: 3.944

3.  Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.

Authors:  Atsushi Isoda; Naru Sato; Yuri Miyazawa; Yoshinobu Matsumoto; Mina Koumoto; Masahito Ookawa; Morio Sawamura; Morio Matsumoto
Journal:  Int J Hematol       Date:  2015-07-16       Impact factor: 2.490

4.  High D-dimer levels are associated with poor prognosis in cancer patients.

Authors:  Cihan Ay; Daniela Dunkler; Robert Pirker; Johannes Thaler; Peter Quehenberger; Oswald Wagner; Christoph Zielinski; Ingrid Pabinger
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

5.  Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations.

Authors:  M Carrier; A Lazo-Langner; S Shivakumar; V Tagalakis; P L Gross; N Blais; C A Butts; M Crowther
Journal:  Curr Oncol       Date:  2015-02       Impact factor: 3.677

6.  Risk of site-specific cancer in incident venous thromboembolism: a population-based study.

Authors:  Tanya M Petterson; Randolph S Marks; Aneel A Ashrani; Kent R Bailey; John A Heit
Journal:  Thromb Res       Date:  2014-12-16       Impact factor: 3.944

7.  Non-vitamin K Antagonist Oral Anticoagulants (NOAC) as an Alternative Treatment Option in Tumor-Related Venous Thromboembolism.

Authors:  Jan Beyer-Westendorf; Robert Klamroth; Stephan Kreher; Florian Langer; Axel Matzdorff; Hanno Riess
Journal:  Dtsch Arztebl Int       Date:  2019-01-18       Impact factor: 5.594

8.  Patient Adherence and Experience with Extended Use of Prophylactic Low-Molecular-Weight Heparin Following Pancreas and Liver Resection.

Authors:  Madeline Lemke; Kaitlyn Beyfuss; Julie Hallet; Natalie G Coburn; Calvin H L Law; Paul J Karanicolas
Journal:  J Gastrointest Surg       Date:  2016-09-29       Impact factor: 3.452

Review 9.  Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data.

Authors:  Marco Paolo Donadini; Francesco Dentali; Alessandro Squizzato; Luigina Guasti; Walter Ageno
Journal:  Intern Emerg Med       Date:  2014-03-25       Impact factor: 3.397

10.  A prospective study on survival in cancer patients with and without venous thromboembolism.

Authors:  Giancarlo Agnelli; Melina Verso; Mario Mandalà; Silvano Gallus; Claudio Cimminiello; Giovanni Apolone; Giovanni Di Minno; Evaristo Maiello; Paolo Prandoni; Armando Santoro; Lucio Crinò; Roberto Labianca
Journal:  Intern Emerg Med       Date:  2013-08-14       Impact factor: 3.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.